戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 ng, in part, to its structural similarity to telithromycin.
2 f hepatic toxicity for causal attribution to telithromycin.
3 ng, in part, to its structural similarity to telithromycin.
4 or probable in their causal association with telithromycin.
5 mparable activity to the commercial ketolide telithromycin.
6 in, and a cladinose-containing derivative of telithromycin.
7  216 strains were found to be susceptible to telithromycin.
8 more active against resistant pathogens than telithromycin.
9                      The current alternative telithromycin (1) from the newer ketolide class of macro
10                                              Telithromycin (2) is a third-generation macrolide antibi
11 e total synthesis of (-)-4,8,10-tridesmethyl telithromycin (3) wherein methyl groups have been replac
12 , the first lipopeptide in clinical use, and telithromycin, a ketolide that is derived from clarithro
13       The first cases of hepatotoxicity with telithromycin, a new class of ketolide antibiotic, were
14 and CO(2)) were used to test the activity of telithromycin against 110 erythromycin-susceptible and 1
15 gher probability, while the effectiveness of telithromycin against the A2058G mutation is explained b
16 ores during the treatment period was 1.3 for telithromycin and 1.0 for placebo (mean difference, -0.3
17 rly twofold increases for clarithromycin and telithromycin and a greater than threefold increase for
18 sistant to two different types of ketolides, telithromycin and ABT-773, but increased slightly the se
19 oach information on the interactions between telithromycin and the 50S ribosome was obtained.
20 xes with the known antibiotics linezolid and telithromycin, as well as with a new, highly potent pleu
21  market introduction, spontaneous reports of telithromycin-associated hepatotoxicity, including frank
22 ed to receive 10 days of oral treatment with telithromycin (at a dose of 800 mg daily) or placebo in
23 tructural analysis showed that the macrolide telithromycin binds in the tunnel of the engineered euka
24 thromycin, clindamycin, virginiamycin S, and telithromycin bound explain why eubacterial ribosomes co
25              Our structure of the antibiotic telithromycin bound to the T. thermophilus ribosome reve
26 olides 6j and 6k in rats differ from that of telithromycin by having higher lung-to-plasma ratios, la
27 resistance mechanism; (ii) susceptibility to telithromycin can be reliably tested by the agar, microd
28                                              Telithromycin can cause severe hepatotoxicity.
29          However, the ketolide antibacterial telithromycin consistently demonstrated in vitro activit
30                                              Telithromycin demonstrated high levels of activity (MIC
31             By disk diffusion with 15-microg telithromycin disks, all strains but one had zones of in
32 al infarction (MI), aripiprazole for MI, and telithromycin for acute liver failure) using Medicaid An
33 nd 1.7+/-1.1 at the end of treatment for the telithromycin group and 2.8+/-1.3 at baseline and 2.0+/-
34 Nausea was more common among patients in the telithromycin group than in the placebo group (P=0.01).
35  The new ketolides cethromycin (ABT-773) and telithromycin have overall antibacterial properties that
36 is study provides evidence of the benefit of telithromycin in patients with acute exacerbations of as
37 controlled study to evaluate the efficacy of telithromycin in patients with acute exacerbations of as
38 nd 6k exhibited better in vivo efficacy than telithromycin in rat lung infection models against Strep
39 m Tracking and Epidemiology for the Ketolide Telithromycin in the United States) surveillance program
40                                              Telithromycin is a ketolide antibiotic approved by the U
41                                  Conclusion: Telithromycin is a rare cause of drug-induced liver inju
42                                              Telithromycin is the first of a new class of ketolide an
43                    The results show that (i) telithromycin is very active against erythromycin-suscep
44                               By comparison, telithromycin MIC(50)s and MIC(90)s for erythromycin-res
45                            Ketolides such as telithromycin mitigate A2058G resistance yet remain susc
46                      The frequency of severe telithromycin-related hepatotoxicity cannot be establish
47 of all cases of liver injury associated with telithromycin reported to FDA as of April 2006 by one of
48                                 The ketolide telithromycin retained activity against all of the isola
49 ractions as well as hydrogen bonding between telithromycin's ARM and U2609.
50 mutation there is significant flexibility in telithromycin's imidazole-pyridine side chain (ARM), ind
51 all organisms were susceptible to a proposed telithromycin susceptibility breakpoint of < or =1 micro
52 acrolide erythromycin (ERY) and the ketolide telithromycin (TEL).
53 y greater reduction among patients receiving telithromycin than among those receiving placebo.
54 ing the macrolide erythromycin, the ketolide telithromycin, the lincosamide clindamycin, and a phenic
55               Within a few days of receiving telithromycin, the patients presented with acute hepatit
56 mpicillin, azithromycin, clarithromycin, and telithromycin was evaluated by altering one variable at
57                                The ketolide, telithromycin, was developed because of rising bacterial
58               Etest MICs of azithromycin and telithromycin were more than twofold higher than agar di
59 evidence also indicates that interactions of telithromycin with the E. coli ribosome more closely res